Publications by authors named "F S Fein"
Background: Studies have reported a beneficial role of the addition of trastuzumab to platin-5-FU based chemotherapy in first-line advanced HER2 positive gastroesophageal adenocarcinoma (GEA). However, the effect of taxanes combined with platin-5FU + trastuzumab (PFT) is understudied.
Methods: We performed a retrospective cohort study to evaluate the interest of taxanes among HER2-positive advanced GEA patients treated with PFT.
Background: FOLFIRINOX regimen is the first-line reference chemotherapy (L1) in advanced pancreatic ductal adenocarcinoma (aPDAC). FOLFOXIRI, a schedule with a lower dose of irinotecan and no bolus 5-fluorouracil, has demonstrated efficacy and feasibility in colorectal cancer.
Aim: To investigate the potential clinical value of FOLFOXIRI in patients with aPDAC in routine clinical practice.
Objective: Diagnostic tests, such as Immunoscore, predict prognosis in patients with colon cancer. However, additional prognostic markers could be detected on pathological slides using artificial intelligence tools.
Design: We have developed a software to detect colon tumour, healthy mucosa, stroma and immune cells on CD3 and CD8 stained slides.
Despite successful introduction of NK-based cellular therapy in the treatment of myeloid leukemia, the potential use of NK alloreactivity in solid malignancies is still elusive. We performed a phase I clinical trial to assess the safety and efficacy of delivery of allogeneic NK cells combined with cetuximab in liver metastasis of gastrointestinal origin. The conditioning chemotherapy was administrated before the allogeneic NK cells injection via hepatic artery.
View Article and Find Full Text PDFHigh Prevalence of Anal Canal High-Risk Human Papillomavirus Infection in Patients With Crohn's Disease.
Clin Gastroenterol Hepatol
November 2018
Article Synopsis
- * HPV DNA was found in 34% of patients, with high-risk HPV (HR-HPV) detected in 18%, notably more prevalent among women (23.1%) and individuals with Crohn's disease (30%).
- * Factors such as female sex, history of STDs, number of sexual partners, smoking, and immunosuppressive therapies were identified as independent risk factors for HR-HPV infection, highlighting the need for better awareness and understanding of this health issue.